Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Posted by: Fred - Tue-20-12-2011, 20:34 PM
- Replies (4)
I'm playing about with "Possibly Related Threads"
At the bottom of a thread you will sometimes see links to other threads that could be similar to the one you are reading. I need to get the settings right so it gives you good alternatives, so your feedback is welcome.
Posted by: Fred - Tue-20-12-2011, 12:40 PM
- No Replies
SCORES of patients will be forced to travel extra miles from their homes for skin treatment after Staffordshire's main hospital suspended its service.
The dermatology department at the University Hospital of North Staffordshire (UHNS) yesterday started sending people still awaiting appointments back to their GPs to be found another centre.
Alternative venues include Congleton War Memorial and Crewe's Leighton hospitals, and centres at Macclesfield, Buxton and Knutsford.
The closure to non-urgent cases comes after the unit at UNHS's central outpatients department was hit by a doubling in the number of referrals from family doctors of patients with ailments which could be cancer.
And that has left its clinics unable to guarantee people with non life-threatening ailments can be under treatment within the 18-week target laid down by the Government.
Even though only 18 patients are breaching the deadline, it means UHNS can no longer be included on the list of choices placed before patients when telling GPs where they want to be seen.
The restrictions affect people with conditions such as acne, psoriasis, eczema, minor skin infections and benign lumps and bumps.
The trust had offered to bring in an extra locum dermatologist to cut the backlog but the area's primary care trusts which fund North Staffordshire's NHS have capped its contracts with hospitals to levels agreed at the start of the financial year in April.
The suspension of the service which sees scores of patients a month is scheduled to last until January 16 but will be reviewed before then.
The suspension left GP leader Dr Paul Golik baffled as the option of referring patients to UHNS was still showing up on his Norton surgery's systems – with the first available appointment being on March 26.
The secretary of the 270-GP local medical committee said: "Other hospitals have no problem getting enough consultants so one wonders why UHNS struggles."
Hospital operations director Dereth Baker said: "We have not taken this action lightly and urgent referrals will continue to be treated. But we are unable to accept patients with non-urgent conditions.
Posted by: Fred - Tue-20-12-2011, 11:28 AM
- No Replies
Combination Treatments for Psoriasis: A Systematic Review and Meta-analysis
Objective: To summarize the current state of evidence for combination topical and systemic therapies for mild to severe psoriasis.
Data Sources: We performed a systematic search for all entries in pub med, CINAHL, Cochrane Review, and EMBASE related to combination treatments for psoriasis through July 2010.
Study Selection: We included randomized controlled trials that reported proportion of disease clearance or mean change in clinical severity score (or provided these data through communication with study authors) for efficacy of a combination treatment for psoriasis compared with 1 or more corresponding monotherapies.
Data Extraction: Study data were extracted by 3 independent investigators, with disagreement resolved by consensus. The proportion of patients who achieved clearance, definition of clearance, means and standard deviations for baseline disease symptom score and final disease symptom score, and major design characteristics were extracted for each study.
Data Synthesis: Combination treatments consisting of vitamin D derivative and corticosteroid, vitamin D derivative and UV-B, vitamin A derivative and psoralen–UV-A, vitamin A derivative and corticosteroid, vitamin A derivative and UV-B, corticosteroid and hydrocolloid occlusion dressings, UV-B and alefacept, and vitamins A and D derivatives were more effective than 1 or more monotherapies using the likelihood of clearance as the outcome. Blinding status and potency of the corticosteroid treatment used were significant sources of heterogeneity between studies.
Conclusions: The results demonstrate the need for additional long-term trials with standardized outcome measures to evaluate the efficacy and adverse effects of combination therapies for psoriasis and highlight the possible effects of trial design characteristics on results.
Today I made my third visit in 2 months to the doc about a dry cough, and sinus pressure. Previously diagnosed bronchitis, but didn't respond to antibiotic. So, I get a chest x-ray, which led to a TB test.
I go back in 2 days to have it read, but based on my own amateur diagnosis (based of course on internet research), it sure looks positive. I have no other symptoms, in fact I feel pretty good apart from the sinusitis and cough. I been getting these TB tests annually since starting Stelara a year and a half ago, and never had any kind of reaction, now I have at least 25mm of induration across the site.
Has anyone experienced this before -- is there any chance this will resolve over the next two days, and be a negative result?
My next injection is coming up, 5 January, I sure don't want to miss it.
Hello,
I'm new to your forum, but not new to psoraisis, having dealt with it for, oh let's see, about 45 years. It was mostly an annoyance for about 35 of those, before it really got bad. So much better now, 1st with Remikade, and now Stelara.
Posted by: Fred - Mon-19-12-2011, 16:13 PM
- No Replies
If you don't like the way posts are shown with the profiles along the top of a post. you can revert back to the Classic view where profiles are shown on the left of posts. (Click image to enlarge)
To revert to classic view go to your User CP and on the left hand side click "Edit Options" then on the right under "Thread View Options" tick the box Display posts in classic mode. scroll down and click "Update Options"
If you want to go back to the modern view just untick the box again and update.
Posted by: Fred - Mon-19-12-2011, 14:23 PM
- Replies (1)
If you are trying to register for membership and you get the following message.
Quote:Your details match those of a known spammer, therefore you have been disallowed registration.
All new registrations have to go through a Stopforumspam.com check. there is nothing we can do for you from this side, and you will need to contact them directly. here is a statement from their website:
Quote:Im listed on your site but Im not a spammer Firstly, its not an accusation of anything. A lot of the information that is listed is gathered from "honeypots" setup to trap spammers. Being listed on the site doesnt mean you have been sending spam. The IP address that you have, mightve been inherited from someone that spammed, someone may have just used your email address or even that you have downloaded a virus or trojan. If you use the removal page and be polite, then we can figure out what has happened and get it fixed.
For more information please see NO LINKS ALLOWED
We also check each registration with NO LINKS ALLOWED If your IP is listed you are likely to get banned. You should take it up with them or your IP provider.
We don't want to stop genuine people from joining Psoriasis Club but we have had to take this action to protect our members. On occasions it could happen that you share your IP with registered spammers, this is unfortunate. and again you should talk to your provider. As a last resort if you have tried all of the above and still feel there is no reason for you not to be a member please contact us and we will see what we can do for you.
Posted by: Fred - Mon-19-12-2011, 12:12 PM
- Replies (1)
AbGenomics International will regain global rights to AbGn-168H from Boehringer Ingelheim, with effect from 13 February 2012.
The move was made following the termination of collaboration between both the companies.
AbGn-168H, a humanized monoclonal antibody against CD-162 preferentially induces apoptosis of late-stage activated T-cells and is under development to treat psoriasis and other immunological diseases.
AbGenomics intends to carry on with the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and hence will seek a new partner.
AbGenomics founder and CEO Rong- Hwa Lin said the company had a good collaboration agreement with Boehringer Ingelheim since 2005.
"While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug," Hwa Lin added.
Posted by: Fred - Thu-15-12-2011, 21:38 PM
- No Replies
Pulsed dye laser therapy may be an attractive new option for treating nail psoriasis, according to Dr. Veronique Blatiere.
Nail psoriasis is challenging to treat because the psoriatic disease process damages the nails while they are still being formed. But Turkish investigators have reported positive results with three once-monthly pulsed dye laser (PDL) treatment sessions in a small uncontrolled patient series, Dr. Blatiere reported at the annual congress of the European Academy of Dermatology and Venereology.
Dr. Yasemin Oram and coworkers at the American Hospital in Istanbul, Turkey, reported on five patients with nail psoriasis treated using PDL. The laser therapy was applied at 595 nm with a pulse duration of 1.5 milliseconds, a beam diameter of 7 mm, and an energy fluence of 8-10 J/cm2. A treatment session was continued until a purple discoloration appeared.
Nail bed lesions, particularly onycholysis and subungual hyperkeratosis, responded to PDL better than did nail matrix lesions. After three treatment sessions, the average Nail Psoriasis Severity Index (NAPSI) score for nail bed lesions dropped from 14.8 to 8.
While the Turkish report is certainly encouraging, it should be viewed as a proof of concept pilot study, said Dr. Blatiere of Saint Eloi University Hospital in Montpellier, France. It needs confirmation with larger numbers of patients, a control arm, and blinded investigator assessment.
Posted by: Fred - Wed-14-12-2011, 11:32 AM
- No Replies
UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following glucagon-like peptide-1 (GLP-1) analogue therapy. Their findings raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions due to the direct impact on innate natural killer T (iNKT) cells.
The clinical team based in St Vincent’s University Hospital found an unexpected improvement in the severity of psoriasis in a patient with type 2 diabetes within days of starting GLP-1 analogue therapy. They surmised this was due to the direct action of GLP-1 on iNKT cells.
The team began treating two obese patients with type 2 diabetes and psoriasis with the GLP-1 analogue, liraglutide. Both patients experienced relief from their psoriasis symptoms within days of starting treatment and the psoriasis area and severity index (PASI) decreased in both.
Describing the laboratory findings, Dr. Andrew E. Hogan, UCD Newman Scholar and senior scientist said, “There was an alteration in iNKT cell number before and after commencing treatment; an increased number in the circulation and decreased number in psoriatic plaques. We also found that iNKT cells expressed GLP-1 receptor and modulated cytokine production”.
Professor Donal O’Shea believes that “Although extensive research will be required to investigate GLP-1 immune cell interactions, the potential benefit for inflammatory conditions such as psoriasis is promising”.
Posted by: Fred - Tue-13-12-2011, 11:25 AM
- No Replies
Enbrel treatment for psoriasis may be associated with an increased risk for multiple squamous cell carcinomas (SCCs), suggest results from a case series and review of the literature.
There is some prior evidence to suggest that anti-tumor necrosis factor drugs such as Enbrel may increase the risk for skin cancers such as SCC, but reports to date have been conflicting.
Writing in the International Journal of Dermatology, Jerry Brewer (Mayo Clinic, Rochester, Minnesota, USA) and colleagues describe four cases of patients with psoriasis and multiple SCCs thought to be a result of Enbrel treatment.
The patients in the series were aged 53 to 85 years and all had lifelong psoriasis. The mean time to first SCC onset was 11 months (range 1-17 months) after beginning Enbrel therapy, with all patients having between five and more than 50 SCCs in total and three of the four patients having aggressive grade III or IV SCCs.
The four psoriasis patients did not have a family history of skin cancer, but all four had previously had SCCs before using Enbrel.
Brewer and team reviewed the literature to evaluate previous reports of links between Enbrel and SCC. They found four further reports of psoriasis patients (n=10) who were treated with Enbrel going on to develop SCC, in one case in addition to non-Hodgkin lymphoma.
In contrast, another study found no increased risk for SCC with Enbrel treatment in 1440 patients with psoriasis. In addition, mice deficient in tumor-necrosis factor-α were shown to be resistant to skin cancer in a further study.
"Although some studies suggest there is no increased risk of cutaneous malignancy in patients treated with Enbrel, more research is needed to better characterize the effect of Enbrel on the development of SCCs in patients with psoriasis," say Brewer and co-authors.
"Until further research is available, sun-protective behavior, education into skin cancer prevention, and regular self-examinations and dermatologic examinations are warranted for patients with psoriasis treated with Enbrel," they conclude.
Posted by: Hanna - Tue-13-12-2011, 10:32 AM
- Replies (1)
I'm wondering if others have had this with their skin, I find it a little worrying!
I have found some strange patterns with my skin, dots going in lines across my body!!
My first lot was a diagonal line from my side (up near breast) comming down across my stomache towards my groin!
I have noticed it on the back of my thigh, and a new line of dots going from the bottom of my ear comming down diagonally accross my neck!!
I spoke to my skin nurse and explained that I had also hurt my hip on the side where the P was comming across stomache, she and a few others said that there is a nerve that runs there and my P was along that line.
I have Koebnerization (cuts turn to P) so can hurt nerves also cause P to come up?
Has anyone else seen similar to this? P along nerve area's
My other thought is that it's something work related.......getting jumped on by over excited dogs!!!
Is there a blood test that rules out P.A? Ill go online shortly...
I am questioning it because i am still nervous about going on drugs, as i may want to get pregnant.
My other question is If you don't have PA, then is the prognosis for
rheumatoid arthritis attacking the ligaments, tendons etc;. the same?
So, possibly one might buy some time without the drugs.
Just took a look at psoriasis dot org, an american website on psoriasis.
Did not get a well impression. The impression is more that is in fact is driven by pharmacy and that they have all cures and knowledge.
And you and I know that that is impossible and certainly not true.
Bit of an arrogant impression so to feel.
They also have a forum talkpsoriasis dot org, don't know if that is something valuable.
Posted by: Fred - Fri-09-12-2011, 16:04 PM
- Replies (1)
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As the leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in all large markets in Europe, in US and Australia”, says Peter Wolpert, President and CEO of Moberg Derma.
About Emtrix® and nail disease
Emtrix® is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a prescription free, over-the-counter product sold under the name Nalox™ in certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006.
About Menarini Group
The Menarini Group celebrates it’s 125thAnniversary this year and is the leading Italian pharmaceutical group in the world, ranking 15thout of 4,881 companies in Europe*and 34thout of 14,051 companies in the world* (*Sources: IMS World Review 2010, IMS World Review Pack 2010 per number of companies). The Group’s 2010 global turnover was 3,031 million Euro. In 2010 the number of employees was 12,890 (91% of which graduates and technicians). The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed them to achieve outstanding results in today’s global market and to invest in the research of innovative drugs, making them available to patients all around the world.
Posted by: Fred - Thu-08-12-2011, 13:03 PM
- No Replies
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated a phase 2 clinical trial in psoriasis patients with the HuCAL-derived antibody CNTO 1959. The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
“With every clinical milestone and every new phase 2 start the time where the first HuCAL-based antibody drug could enter the market gets closer. MorphoSys’s antibody pipeline has substantially matured over the last 18 months,” commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
In total, MorphoSys’s clinical pipeline now comprises nine partnered programs in phase 1 and seven in phase 2 development as well as the Company’s proprietary programs MOR103, which is in a phase 1b/2a trial for rheumatoid arthritis, MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 982 » Latest member: Trinitee » Forum threads: 7,128 » Forum posts: 260,609
There are currently 187 online users. »0 Member(s) | 186 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.